Sign in

You're signed outSign in or to get full access.

Alice Schroeder

Director at Dakota Gold
Board

About Alice Schroeder

Alice Schroeder (age 68) has served as an independent director of Dakota Gold Corp. since August 2022. She is Chair of the Audit Committee and a member of the Compensation and Nominating & Corporate Governance Committees. A CPA who began her career at Ernst & Young, she spent nearly two decades on Wall Street as an analyst and banker, principally at Morgan Stanley, and holds a BBA and MBA from the University of Texas at Austin .

Past Roles

OrganizationRoleTenureCommittees/Impact
Prudential plcNon-Executive DirectorJun 2013 – May 2022Served/chaired audit, compensation, nominating/governance, sustainability committees across boards (general)
HSBC North America Holdings Inc.DirectorOct 2021 – presentServes on audit committees of two other public companies; nominated to a third; plans to resign from one if elected
Carbon Streaming CorporationDirectorJan 2022 – presentBoard service; committee experience noted above
Natus Medical IncorporatedDirectorFeb 2019 – Jul 2022Board service; committee experience noted above
Bank of America Merrill Lynch InternationalDirector (private)Feb 2016 – Dec 2018Board service
RefleXion Medical, Inc.Director (private/venture)Apr 2021 – presentBoard service
Cetera Financial GroupDirector (PE-backed)Apr 2012 – Apr 2014Board service
Westland Insurance Group LimitedDirector (PE-backed)Feb 2021 – May 2023Board service
Quorum Health CorporationDirectorJun 2018 – Jul 2021Board service

External Roles

CompanyRole/CommitteeSince
HSBC North America Holdings Inc.Director; serves on audit committee of two other public companies (unnamed in proxy) Oct 2021 – present
Carbon Streaming CorporationDirectorJan 2022 – present
Dakota Gold Corp.Director; Audit Committee ChairAug 2022 – present

Overboarding note: DC policy generally limits Audit Committee members to ≤2 other public-company audit committees. The Board determined Ms. Schroeder’s temporary service on >2 would not impair effectiveness; she intends to resign from one audit committee if elected to another board (expected May 2025) .

Board Governance

  • Independence: The Board determined Ms. Schroeder is independent under NYSE American, SOX 10A(m)(3), and Exchange Act standards .
  • Committee assignments (FY 2024/2025): Audit (Chair); Compensation (member); Nominating & Corporate Governance (member). Ms. Schroeder qualifies as an “Audit Committee Financial Expert.” Committee meetings held in FY 2024: Audit 4, Compensation 4, N&CG 3 .
  • Attendance: Each incumbent director attended all regularly scheduled Board and committee meetings during FY 2024; all directors attended the 2024 annual meeting .
  • Audit Committee practices: Committee holds executive sessions with independent auditors when appropriate .

Fixed Compensation

ComponentFY 2023 Amount (USD)FY 2024 Amount (USD)Notes
Cash retainer$50,000 $50,000 Paid $12,500 per quarter in 2024
Equity (Stock Awards, grant-date fair value)$100,000 $100,000 RSUs granted Mar 1, 2023 and Mar 1, 2024; vest ratably over 3 anniversaries
OptionsNo option awards to directors in these years
Total$150,000 $150,000
  • Mix and alignment: Equity was ~67% of total director compensation in both 2023 and 2024 based on reported grant-date fair values .

Performance Compensation

Performance Metric(s) Applied to Director PayStatus
Performance-based metrics tied to director equity (e.g., PSUs)None disclosed; director grants were time-vested RSUs (3-year ratable vesting)

Plan terms: Under the 2022 Stock Incentive Plan, RSUs and options are fully accelerated and PSUs accelerate at target upon a change of control (plan description provided in proxy; illustrated in NEO context) .

Other Directorships & Interlocks

CompanyRelationship to DCInterlock/Conflict Notes
HSBC North America Holdings Inc.UnrelatedNo DC-related interlock disclosed; serves on audit committees at two other public companies
Carbon Streaming CorporationUnrelatedNo DC-related interlock disclosed
Prior boards (e.g., Prudential plc, Natus Medical)UnrelatedNo DC-related interlocks disclosed in proxy
  • Related-party transactions: Proxy discloses related-party transactions and review process. The examples disclosed do not name Ms. Schroeder; independence was affirmed by the Board .

Expertise & Qualifications

  • CPA; early career at Ernst & Young; ~20 years on Wall Street as analyst/banker (MD, primarily Morgan Stanley) .
  • Recognized Audit Committee Financial Expert; extensive experience chairing/serving on audit, compensation, nomination/governance, and sustainability committees .
  • Education: BBA and MBA, University of Texas at Austin .

Equity Ownership

As-of DateBeneficially Owned Shares% of ClassBreakdown
Mar 20, 2024308,138 0.35% Not itemized in table excerpt
Mar 14, 2025369,057 * (<1%) 260,039 common shares; 100,000 vested options; 9,018 warrants
  • Shares outstanding at record date: 99,032,807 (Mar 14, 2025) .
  • Hedging/short sales: Company insider trading policy expressly prohibits hedging and short sales by directors .

Insider Trades and Compliance

ItemFY 2024 Status
Section 16(a) filings by directorsTimely filed, per proxy disclosure
Hedging/short sales by directorsProhibited by policy

Governance Assessment

  • Strengths

    • Independent director; Audit Committee Chair and Audit Committee Financial Expert; strong attendance and engagement (100% of regularly scheduled Board/committee meetings in 2024) .
    • Material equity alignment via time-vested RSUs (grant-date FV $100,000) alongside modest cash retainer ($50,000); equity comprises majority of director pay .
    • Growing personal stake: 369,057 shares beneficially owned as of Mar 14, 2025, including 260,039 shares, 100,000 vested options, 9,018 warrants; <1% of outstanding .
    • Robust audit oversight practices, including executive sessions with auditors; meets frequency expectations (Audit met 4x in FY 2024) .
    • Hedging/short sales prohibited under insider trading policy .
  • Watch items / potential risks

    • Temporary “overboarding” on audit committees: Serving on two other public-company audit committees with a potential third pending; DC’s policy limits members to ≤2 unless the Board determines otherwise (Board allowed temporary exception; Ms. Schroeder intends to resign from one after the other company’s annual meeting expected May 2025) .
    • Related-party governance framework: DC lacks a formal written related-party transaction policy (relies on Audit Committee charter and Code of Ethics for review/approval). No transactions involving Ms. Schroeder were disclosed, and her independence was affirmed, but the absence of a standalone formal policy can be viewed as a governance weakness by some investors .
  • Overall implication: Ms. Schroeder brings deep financial expertise and strong governance credentials as Audit Chair and ACF Expert, with solid attendance and equity alignment. The temporary audit-committee overboarding should be monitored until resolved per the Board’s disclosure, but the Board has addressed it and disclosed the mitigation plan, partially offsetting investor concern .